11:14:02 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-06 Kvartalsrapport 2024-Q3
2024-08-08 Kvartalsrapport 2024-Q2
2024-05-02 Kvartalsrapport 2024-Q1
2024-03-14 X-dag ordinarie utdelning GMAB 0.00 DKK
2024-03-13 Årsstämma 2024
2024-02-14 Bokslutskommuniké 2023
2023-11-07 Kvartalsrapport 2023-Q3
2023-08-03 Kvartalsrapport 2023-Q2
2023-05-10 Kvartalsrapport 2023-Q1
2023-03-30 X-dag ordinarie utdelning GMAB 0.00 DKK
2023-03-29 Årsstämma 2023
2023-02-22 Bokslutskommuniké 2022
2022-11-09 Kvartalsrapport 2022-Q3
2022-08-10 Kvartalsrapport 2022-Q2
2022-05-11 Kvartalsrapport 2022-Q1
2022-03-30 X-dag ordinarie utdelning GMAB 0.00 DKK
2022-03-29 Årsstämma 2022
2022-02-16 Bokslutskommuniké 2021
2021-11-10 Kvartalsrapport 2021-Q3
2021-08-11 Kvartalsrapport 2021-Q2
2021-05-05 Kvartalsrapport 2021-Q1
2021-04-14 X-dag ordinarie utdelning GMAB 0.00 DKK
2021-04-13 Årsstämma 2021
2021-02-23 Bokslutskommuniké 2020
2020-11-04 Kvartalsrapport 2020-Q3
2020-08-12 Kvartalsrapport 2020-Q2
2020-05-06 Kvartalsrapport 2020-Q1
2020-03-27 X-dag ordinarie utdelning GMAB 0.00 DKK
2020-03-26 Årsstämma 2020
2020-02-19 Bokslutskommuniké 2019
2019-04-01 X-dag ordinarie utdelning GMAB 0.00 DKK
2019-03-29 Årsstämma 2019
2018-11-14 Kvartalsrapport 2018-Q3
2018-08-08 Kvartalsrapport 2018-Q2
2018-05-08 Kvartalsrapport 2018-Q1
2018-04-11 X-dag ordinarie utdelning GMAB 0.00 DKK
2018-04-10 Årsstämma 2018
2018-02-21 Bokslutskommuniké 2017
2017-11-08 Kvartalsrapport 2017-Q3
2017-08-09 Kvartalsrapport 2017-Q2
2017-05-10 Kvartalsrapport 2017-Q1
2017-03-29 X-dag ordinarie utdelning GMAB 0.00 DKK
2017-03-28 Årsstämma 2017
2017-02-22 Bokslutskommuniké 2016
2016-11-10 Kapitalmarknadsdag 2016
2016-11-02 Kvartalsrapport 2016-Q3
2016-08-09 Kvartalsrapport 2016-Q2
2016-05-10 Kvartalsrapport 2016-Q1
2016-03-18 X-dag ordinarie utdelning GMAB 0.00 DKK
2016-03-17 Årsstämma 2016
2016-02-17 Bokslutskommuniké 2015
2015-11-03 Kvartalsrapport 2015-Q3
2015-08-11 Kvartalsrapport 2015-Q2
2015-05-12 Kvartalsrapport 2015-Q1
2015-03-27 X-dag ordinarie utdelning GMAB 0.00 DKK
2015-03-26 Årsstämma 2015
2015-03-02 Bokslutskommuniké 2014
2014-11-05 Kvartalsrapport 2014-Q3
2014-08-13 Kvartalsrapport 2014-Q2
2014-05-07 Kvartalsrapport 2014-Q1
2014-04-10 X-dag ordinarie utdelning GMAB 0.00 DKK
2014-04-09 Årsstämma 2014
2014-03-04 Bokslutskommuniké 2013
2013-11-06 Kvartalsrapport 2013-Q3
2013-08-14 Kvartalsrapport 2013-Q2
2013-05-07 Kvartalsrapport 2013-Q1
2013-04-18 X-dag ordinarie utdelning GMAB 0.00 DKK
2013-04-17 Årsstämma 2013
2013-03-07 Bokslutskommuniké 2012
2012-11-07 Kvartalsrapport 2012-Q3
2012-08-15 Kvartalsrapport 2012-Q2
2012-05-09 Kvartalsrapport 2012-Q1
2012-04-26 X-dag ordinarie utdelning GMAB 0.00 DKK
2012-04-25 Årsstämma 2012
2011-11-02 Kvartalsrapport 2011-Q3
2011-08-03 Kvartalsrapport 2011-Q2
2011-05-11 Kvartalsrapport 2011-Q1
2011-04-07 X-dag ordinarie utdelning GMAB 0.00 DKK
2011-04-06 Årsstämma 2011
2011-02-28 Bokslutskommuniké 2010
2010-04-22 X-dag ordinarie utdelning GMAB 0.00 DKK

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriBioteknik
Genmab är ett läkemedelsbolag. Bolaget är specialiserat inom forskning och utveckling av antikroppar, som huvudsakligen används vid behandling av cancerpatienter med lymfatisk leukemi och solida tumörer. Forskning och utveckling utgår ifrån bolagets egenutvecklade tekniska plattform och verksamhet innehas på global nivå. Genmab grundades 1999 och har sitt huvudkontor i Köpenhamn, Danmark.
2024-06-03 15:09:23

Company Announcement

COPENHAGEN, Denmark; June 3, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares.
The share buy-back program is expected to be completed no later than December 16, 2024.

The following transactions were executed under the program from May 27, 2024 to May 31, 2024:

  Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)
Accumulated through
last announcement
  

799,099
 1,609,560,257.36
May 27, 2024XCSE32,4951,952.69 
 CEUX13,7141,953.29 
 AQEU2,518                 1,953.34 
 TQEX2,2241,953.39 
 Total50,9511,952.9199,502,788.74
May 28, 2024XCSE30,2441,957.87 
 CEUX13,418                 1,961.65 
 AQEU1,7441,957.51 
 TQEX1,9941,957.75 
 Total47,4001,958.9292,852,992.86
May 29, 2024XCSE26,4291,924.99 
 CEUX13,0401,924.24 
 AQEU1,4841,925.96 
 TQEX2,0701,924.34 
 Total43,0231,924.7682,809,104.36
May 30, 2024XCSE31,371                 1,922.78 
 CEUX13,210 1,916.59 
 AQEU2,202                 1,922.60 
 TQEX2,143 1,916.71 
 Total48,9261,920.8393,978,729.18
May 31, 2024XCSE25,2861,932.26 
 CEUX13,3731,929.83 
 AQEU2,2861,929.50 
 TQEX2,0771,929.51 
 Total43,0221,931.2283,085,136.14
Total 233,322 452,228,751.28
Accumulated under the program 1,032,421 2,061,789,008.64
      

Details of each transaction are included as an appendix to this announcement.

Following these transactions, Genmab holds 1,881,559 shares as treasury shares, corresponding to 2.85% of the total share capital and voting rights.

The share buy-back program is undertaken in accordance with Regulation (EU) No. 596/2014 (‘MAR’) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the “Safe Harbour Regulation.” Further details on the terms of the share buy-back program can be found in our company announcement no. 22 dated March 15, 2024.

About Genmab
Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative, and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies, and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO®) antibody medicines.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.

Contact:          
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®.

Company Announcement no. 40
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark